TEVA, US8816242098

Piper Sandler sets USD 44.00 target for Teva stock ahead of results

Published on 10/26/2026 at 09:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva posted USD 4.14 billion revenue and a USD 576.00 million loss in the second quarter. Teva stock last stood at USD 39.41 on October 23, 2026.

Targets and quarterly results

Piper Sandler set a USD 44.00 target for Teva on October 23, 2026.
Second-quarter revenue reached USD 4.14 billion while the company posted a USD 576.00 million loss.
Teva is scheduled to report third-quarter results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries (ISIN US8816242098) drew a USD 44.00 price target from Piper Sandler on October 23, 2026, while the analyst reiterated a Buy rating, Markets Insider reported. The call comes before Teva's scheduled third-quarter results.

Three targets since October 12

On October 12, 2026, JPMorgan raised its Teva target from USD 40.00 to USD 50.00 after the Weltruza approval, according to Investing.com. On October 15, 2026, Barclays lifted its target from USD 42.00 to USD 47.00 and kept an Overweight rating, Markets Insider reported. On October 23, 2026, Piper Sandler set the USD 44.00 target and reiterated Buy, according to Markets Insider.

What do the targets imply?

The target gap is USD 6.00: JPMorgan's USD 50.00 objective exceeds Piper Sandler's USD 44.00 objective. The range shows that the analyst view depends on how quickly Weltruza and Teva's broader pipeline translate into sales.

Teva's second-quarter 2026 revenue was USD 4.14 billion versus USD 4.18 billion a year earlier, while its GAAP result shifted from a USD 282.00 million profit to a USD 576.00 million loss, according to Markets Insider. That earnings contrast gives the upcoming report a sharper test than the target revisions alone.

Upcoming dates include November 3

Teva is scheduled to discuss third-quarter 2026 financial results on November 3, 2026, at 8:00 a.m. ET, according to gettex. The company is also set to host an R&D Day in New York on November 11, 2026, the same event listing shows through gettex.

NYSE valuation before the report

On the NYSE, Teva last stood at USD 39.41 on October 23, 2026, at 4:00 p.m. ET. Its market capitalization was USD 45.9 billion, while the 52-week range was USD 19.00 to USD 42.02 as of that date.